<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576508</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-4975i-OA-102</org_study_id>
    <nct_id>NCT03576508</nct_id>
  </id_info>
  <brief_title>A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis</brief_title>
  <official_title>A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza速) in Subjects With Painful Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrexion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrexion Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, two-period, randomized crossover study in adult male and
      female participants with painful knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">September 6, 2018</completion_date>
  <primary_completion_date type="Actual">September 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capsaicin Pharmacokinetics - AUC0-t</measure>
    <time_frame>Day 1 (pre-dose to 12 hours post-dose) and Day 8 (pre-dose to 12 hours post-dose)</time_frame>
    <description>Single-dose systemic exposure to trans- and cis-capsaicin measured by AUC0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Capsaicin Pharmacokinetics - AUC0-inf</measure>
    <time_frame>Day 1 (pre-dose to 12 hours post-dose) and Day 8 (pre-dose to 12 hours post-dose)</time_frame>
    <description>Single-dose systemic exposure to trans- and cis-capsaicin measured by AUC0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Capsaicin Pharmacokinetics - Cmax</measure>
    <time_frame>Day 1 (pre-dose to 12 hours post-dose) and Day 8 (pre-dose to 12 hours post-dose)</time_frame>
    <description>Single-dose systemic exposure to trans- and cis-capsaicin measured by Cmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS) Assessment</measure>
    <time_frame>Day 1 (pre-dose) or Day 8 (pre-dose) [cross over trial Qutenza速 8% patch or CNTX-4975-05 intra-articular (IA) knee injection], and Week 8 (follow-up)</time_frame>
    <description>Change from baseline in KOOS of IA injected knees; 5-point Likert scale: 0 (no problems) to 4 (extreme problems); 5 subscales; each assessed separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) (safety and tolerability)</measure>
    <time_frame>Day 1 (post-dose), Day 8 (post-dose), and Week 8 (follow-up)</time_frame>
    <description>Number of participants with TEAEs, which includes laboratory test variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IA knee Lidocaine Systemic Pharmacokinetics - Concentration</measure>
    <time_frame>Day 1 (pre-dose to 3 hours post-dose) or Day 8 (pre-dose to 3 hours post-dose) [Cross over trial Qutenza速 8% patch or CNTX-4975-05 IA knee injection]</time_frame>
    <description>System exposure to lidocaine measured by plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>CNTX-4975-05 Intra-Articular (IA) Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives IA injection into the most painful OA knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical 8% Capsaicin Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives Capsaicin Patch on posterior rib cage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTX-4975-05</intervention_name>
    <description>1 mg (2mL) IA injection</description>
    <arm_group_label>CNTX-4975-05 Intra-Articular (IA) Injection</arm_group_label>
    <other_name>trans-capsaicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qutenza</intervention_name>
    <description>8% topical patch</description>
    <arm_group_label>Topical 8% Capsaicin Patch</arm_group_label>
    <other_name>cis-capsaicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine (without epinephrine)</intervention_name>
    <description>15 mL IA injection of 2% lidocaine (without epinephrine)</description>
    <arm_group_label>CNTX-4975-05 Intra-Articular (IA) Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body mass index (BMI) between 18.0-35.0 kg/m^2

          -  Subject has moderate to severe painful osteoarthritis in one knee while walking (index
             knee); contralateral knee may or may not have osteoarthritis, pain should be none to
             mild in the non-index knee

          -  Confirmation of the OA of the index knee: American College of Rheumatology (ACR)
             diagnostic criteria

          -  Subject has intact skin at the location of the dosing sites (patch or injection)

        Key Exclusion Criteria:

          -  Subject has any other form of arthritis, such as, but not limited to, rheumatoid
             arthritis, psoriatic arthritis, gout, systemic lupus erythematosus, etc.

          -  Subject has a dermatological condition that may contraindicate participation,
             including any compromise in skin integrity at the CNTX-4975-05 injection site or the
             Qutenza速 skin application site, e.g., severe or cystic acne, psoriasis, eczema, atopic
             dermatitis, active or treated cancer, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Stevens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centrexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Well Pharma Medical Research, Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

